← Back to patent-cliff list
lartesertib
Tier C — Watch / tradelartesertib
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：ATM
Indications (approved)：Ovarian cancer, Epithelial ovarian cancer, Solid tumour
Regional status
US
Phase II
2024-10-30
EU
Phase II
2024-10-30
China
Phase I
2025-06-13
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of lartesertib?
Approved indications include: Ovarian cancer, Epithelial ovarian cancer, Solid tumour.
When does the lartesertib patent expire?
No public expiry year is available for lartesertib yet; this page updates once verified.
How do I get a quote for lartesertib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01